Aura Biosciences, Inc.(AURA)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

AURA Aura Biosciences, Inc.

盘前交易 10-01 07:47:36 EDT

6.28

+0.13

+2.11%

盘前6.17

-0.11-1.75%

07:45 EDT

最高6.36	最低6.12	成交量67.75万
今开6.21	昨收6.15	日振幅3.90%
总市值6.49亿	流通市值5.02亿	总股本1.03亿
成交额424.24万	换手率0.85%	流通股本7,992万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"AURA","market":"US","secType":"STK","nameCN":"Aura Biosciences, Inc.","latestPrice":6.28,"timestamp":1790798400000,"preClose":6.15,"halted":0,"volume":677458,"hourTrading":{"tag":"盘前","latestPrice":6.17,"preClose":6.28,"latestTime":"07:45 EDT","volume":1314,"amount":8365.2519744,"timestamp":1790855150057,"change":-0.11,"changeRate":-0.017516,"amplitude":0.079618},"delay":0,"changeRate":0.021138211382113803,"floatShares":79915500,"shares":103386600,"eps":-1.77265,"marketStatus":"盘前交易","change":0.13,"latestTime":"10-01 07:47:36 EDT","open":6.21,"high":6.36,"low":6.12,"amount":4242419.6932334,"amplitude":0.039024,"askPrice":8.13,"askSize":100,"bidPrice":5.75,"bidSize":5,"shortable":3,"etf":0,"ttmEps":-1.77265,"tradingStatus":1,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1790861400000},"marketStatusCode":1,"adr":0,"listingDate":1635480000000,"exchange":"NASDAQ","adjPreClose":6.28,"preHourTrading":{"tag":"盘前","latestPrice":6.17,"preClose":6.28,"latestTime":"07:45 EDT","volume":1314,"amount":8365.2519744,"timestamp":1790855150057,"change":-0.11,"changeRate":-0.017516,"amplitude":0.079618},"postHourTrading":{"tag":"盘后","latestPrice":6.28,"preClose":6.28,"latestTime":"19:30 EDT","volume":30088,"amount":188952.76,"timestamp":1790811003174,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.7705722562739423,"impliedVol":2.8898,"impliedVolPercentile":0.8},"requestUrl":"/m/hq/s/AURA","defaultTab":"news","newsList":[{"id":"2659119758","title":"一汽-大众ID. AURA T6接入豆包大模型","url":"https://stock-news.laohu8.com/highlight/detail?id=2659119758","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2659119758?lang=zh_cn&edition=full","pubTime":"2026-08-14 15:53","pubTimestamp":1786693981,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["WISE","AURA","EPAI","BK4139","GPTZ","LRNZ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1165877982","title":"Aura Biosciences——与Jefferies签署销售协议，或可出售至多2亿美元普通股（SEC文件披露）","url":"https://stock-news.laohu8.com/highlight/detail?id=1165877982","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1165877982?lang=zh_cn&edition=full","pubTime":"2026-08-12 04:19","pubTimestamp":1786479572,"startTime":"0","endTime":"0","summary":"Aura Biosciences, Inc. 近日披露，根据其与投行Jefferies签署的一份销售协议，公司可能出售至多2亿美元的普通股。这一信息源自美国证券交易委员会（SEC）的相关申报文件。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","AURA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1137039353","title":"组织重组与资本配置助力Aura Biosciences将现金流跑道延长至2029年上半年","url":"https://stock-news.laohu8.com/highlight/detail?id=1137039353","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1137039353?lang=zh_cn&edition=full","pubTime":"2026-08-11 19:06","pubTimestamp":1786446396,"startTime":"0","endTime":"0","summary":"Aura Biosciences（Aura Biosciences, Inc.）通过实施组织重组与资本配置策略，显著延长了其现金储备的可持续性，现预期可支撑公司运营至2029年上半年。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AURA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1190931214","title":"Aura Biosciences III期COMPASS试验完成108名患者入组，顶线数据预计2027年下半年读出","url":"https://stock-news.laohu8.com/highlight/detail?id=1190931214","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1190931214?lang=zh_cn&edition=full","pubTime":"2026-08-11 19:06","pubTimestamp":1786446369,"startTime":"0","endTime":"0","summary":"Aura Biosciences公司宣布，其关键的III期COMPASS临床试验已经完成全部患者入组，共计108名受试者。这一里程碑标志着该研究进入关键数据收集阶段。根据公司预期，顶线结果将在2027年下半年对外公布。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AURA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655490806","title":"一汽-大众ID. AURA T6开启盲订","url":"https://stock-news.laohu8.com/highlight/detail?id=2655490806","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2655490806?lang=zh_cn&edition=full","pubTime":"2026-07-30 22:51","pubTimestamp":1785423115,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["AURA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644971777","title":"XREAL发布Android XR眼镜AURA：重不到95克集成Gemini AI，今秋上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2644971777","media":"凤凰网科技","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2644971777?lang=zh_cn&edition=full","pubTime":"2026-06-17 11:21","pubTimestamp":1781666478,"startTime":"0","endTime":"0","summary":"软件层面，XREAL AURA深度整合Google Android XR生态及Gemini AI能力。XREAL透露，目前已有数百套开发者套件通过Google此前发布的Android XR Catalyst Developer Program发放至全球开发者手中，以推动娱乐、办公、医疗、体育等领域的XR应用开发。XREAL AURA已在官网开放预订，美国、英国和日本用户可支付99美元参与预订。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://tech.ifeng.com/c/8u1j0XEFImp","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"ifeng_tech","symbols":["CHAT","AIPO","AGIX","AURA","ARTY","BK4139","IPOS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1137059152","title":"Aura Biosciences宣布Bel-SAR治疗早期脉络膜黑色素瘤的3期Compass试验完成患者入组","url":"https://stock-news.laohu8.com/highlight/detail?id=1137059152","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1137059152?lang=zh_cn&edition=full","pubTime":"2026-06-01 20:00","pubTimestamp":1780315253,"startTime":"0","endTime":"0","summary":"Aura Biosciences, Inc. 近日宣布，其针对早期脉络膜黑色素瘤的在研疗法Bel-SAR，其关键性3期临床试验“Compass”已完成全部患者入组工作。这一里程碑标志着该创新疗法在临床开发道路上迈出了至关重要的一步，为后续的数据收集与分析奠定了坚实基础。脉络膜黑色素瘤是一种罕见但严重的眼内恶性肿瘤，Bel-SAR作为一种新型靶向疗法，旨在为患者提供一种潜在的有效治疗选择。此次试验的顺利推进，有望为满足这一未竟的医疗需求带来新的希望。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","AURA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1121003754","title":"Aura Biosciences完成2.99亿美元公开发行 承销商超额配售权全额行使","url":"https://stock-news.laohu8.com/highlight/detail?id=1121003754","media":"投资观察","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1121003754?lang=zh_cn&edition=full","pubTime":"2026-05-06 05:17","pubTimestamp":1778015852,"startTime":"0","endTime":"0","summary":"临床阶段生物技术公司Aura Biosciences, Inc.今日宣布完成此前公布的承销公开发行。本次发行中，公司以每股6.00美元的价格累计发售46,099,650股普通股，其中包含承销商全额行使超额配售权认购的6,508,650股。同时向特定投资者发行了可认购总计380万股普通股的预融资权证，行权价格为每份0.00001美元，权证发行价为每股5.99999美元。在扣除承销折扣及发行费用前，本次发行预计为Aura Biosciences募集约2.994亿美元总收益。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AURA","USA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1192237923","title":"Aura Biosciences敲定2.6亿美元普通股及预融资权证公开发行定价","url":"https://stock-news.laohu8.com/highlight/detail?id=1192237923","media":"美股速递","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1192237923?lang=zh_cn&edition=full","pubTime":"2026-05-04 21:05","pubTimestamp":1777899914,"startTime":"0","endTime":"0","summary":"Aura Biosciences, Inc.已正式公布其普通股及预融资权证公开发行的最终定价。此次融资总规模达2.6亿美元，标志着该公司资本运作的重要进展。\n通过本次发行，公司旨在为核心管线产品的临床开发及企业运营注入新动能。市场将密切关注此次融资对Aura Biosciences长期发展战略的推进作用。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","AURA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1162111026","title":"Aura Biosciences预计III期COMPASS试验将于2026年中完成入组，2027年下半年公布顶线数据","url":"https://stock-news.laohu8.com/highlight/detail?id=1162111026","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1162111026?lang=zh_cn&edition=full","pubTime":"2026-05-04 18:02","pubTimestamp":1777888941,"startTime":"0","endTime":"0","summary":"生物技术公司Aura Biosciences, Inc.宣布，其关键性III期COMPASS临床试验的受试者招募工作预计在2026年中期完成。该公司同时披露，这项重要研究的顶线数据结果计划于2027年下半年对外公布。\n此次临床试验的推进标志着公司在眼科药物研发领域取得重要进展。研究进度的明确为市场提供了清晰的时间表，有助于投资者评估公司未来的发展里程碑。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AURA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1121615067","title":"Aura Biosciences首席执行官兼总裁Elisabet De Los Pinos将于2026年4月30日卸任","url":"https://stock-news.laohu8.com/highlight/detail?id=1121615067","media":"美股速递","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1121615067?lang=zh_cn&edition=full","pubTime":"2026-05-04 18:02","pubTimestamp":1777888931,"startTime":"0","endTime":"0","summary":"生物技术公司Aura Biosciences Inc.宣布，其首席执行官、总裁及董事会成员Elisabet De Los Pinos女士，将于2026年4月30日正式卸任所有职务。\n这一重大人事变动标志着公司领导层即将迎来新的篇章。De Los Pinos的离任细节及继任安排尚未公布，市场密切关注后续发展。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AURA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2514859216","title":"Aura Biosciences, Inc.盘中异动 早盘股价大涨5.15%","url":"https://stock-news.laohu8.com/highlight/detail?id=2514859216","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2514859216?lang=zh_cn&edition=full","pubTime":"2025-02-26 22:40","pubTimestamp":1740580839,"startTime":"0","endTime":"0","summary":"北京时间2025年02月26日22时40分，Aura Biosciences, Inc.股票出现异动，股价大幅拉升5.15%。Aura Biosciences, Inc.股票所在的生物技术行业中，整体跌幅为0.56%。Aura Biosciences, Inc.公司简介：Aura Biosciences Inc 是一家临床阶段的生物技术公司，正在开发精准免疫疗法，用于治疗一系列固体肿瘤，旨在保护受癌症影响的器官功能。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250226224039abddef59&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250226224039abddef59&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","AURA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2505861359","title":"Aura Biosciences, Inc.盘中异动 急速下跌5.19%报7.68美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2505861359","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2505861359?lang=zh_cn&edition=full","pubTime":"2025-01-24 23:00","pubTimestamp":1737730846,"startTime":"0","endTime":"0","summary":"北京时间2025年01月24日23时00分，Aura Biosciences, Inc.股票出现异动，股价急速跳水5.19%。Aura Biosciences, Inc.股票所在的生物技术行业中，整体跌幅为0.44%。Aura Biosciences, Inc.公司简介：Aura Biosciences Inc 是一家临床阶段的生物技术公司，正在开发精准免疫疗法，用于治疗一系列固体肿瘤，旨在保护受癌症影响的器官功能。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250124230047960f9354&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250124230047960f9354&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","AURA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2492161244","title":"Aura Biosciences, Inc.盘中异动 急速上涨5.29%报8.86美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2492161244","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2492161244?lang=zh_cn&edition=full","pubTime":"2024-12-17 01:18","pubTimestamp":1734369487,"startTime":"0","endTime":"0","summary":"北京时间2024年12月17日01时18分，Aura Biosciences, Inc.股票出现异动，股价急速上涨5.29%。Aura Biosciences, Inc.股票所在的生物技术行业中，整体涨幅为1.02%。Aura Biosciences, Inc.公司简介：Aura Biosciences Inc 是一家临床阶段的生物技术公司，正在开发精准免疫疗法，用于治疗一系列固体肿瘤，旨在保护受癌症影响的器官功能。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241217011807a1f38d3f&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241217011807a1f38d3f&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["AURA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2489324992","title":"Aura Biosciences, Inc.盘中异动 急速上涨5.68%报8.75美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2489324992","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2489324992?lang=zh_cn&edition=full","pubTime":"2024-12-06 23:37","pubTimestamp":1733499471,"startTime":"0","endTime":"0","summary":"北京时间2024年12月06日23时37分，Aura Biosciences, Inc.股票出现波动，股价大幅拉升5.68%。Aura Biosciences, Inc.股票所在的生物技术行业中，整体涨幅为0.69%。Aura Biosciences, Inc.公司简介：Aura Biosciences Inc 是一家临床阶段的生物技术公司，正在开发精准免疫疗法，用于治疗一系列固体肿瘤，旨在保护受癌症影响的器官功能。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241206233751a1d9915b&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241206233751a1d9915b&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["AURA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2488940394","title":"Aura Biosciences, Inc.盘中异动 早盘大幅下挫5.09%","url":"https://stock-news.laohu8.com/highlight/detail?id=2488940394","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2488940394?lang=zh_cn&edition=full","pubTime":"2024-12-03 23:53","pubTimestamp":1733241212,"startTime":"0","endTime":"0","summary":"北京时间2024年12月03日23时53分，Aura Biosciences, Inc.股票出现波动，股价快速下跌5.09%。Aura Biosciences, Inc.股票所在的生物技术行业中，整体跌幅为0.49%。Aura Biosciences, Inc.公司简介：Aura Biosciences Inc 是一家临床阶段的生物技术公司，正在开发精准免疫疗法，用于治疗一系列固体肿瘤，旨在保护受癌症影响的器官功能。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241203235332abf32267&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241203235332abf32267&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","AURA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2483207581","title":"Aura Biosciences, Inc.盘中异动 下午盘股价大跌5.22%报9.45美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2483207581","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2483207581?lang=zh_cn&edition=full","pubTime":"2024-11-16 03:34","pubTimestamp":1731699248,"startTime":"0","endTime":"0","summary":"北京时间2024年11月16日03时34分，Aura Biosciences, Inc.股票出现波动，股价急速下挫5.22%。Aura Biosciences, Inc.股票所在的生物技术行业中，整体跌幅为3.85%。Aura Biosciences, Inc.公司简介：Aura Biosciences Inc 是一家临床阶段的生物技术公司，正在开发精准免疫疗法，用于治疗一系列固体肿瘤，旨在保护受癌症影响的器官功能。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241116033408a23be6fd&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241116033408a23be6fd&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["AURA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2483306195","title":"Aura Biosciences, Inc.2024财年第三财季实现净利润-21.04百万美元，同比减少13.67%","url":"https://stock-news.laohu8.com/highlight/detail?id=2483306195","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2483306195?lang=zh_cn&edition=full","pubTime":"2024-11-16 00:00","pubTimestamp":1731686436,"startTime":"0","endTime":"0","summary":"11月16日，Aura Biosciences, Inc.公布财报，公告显示公司2024财年第三财季净利润为-21.04百万美元，同比减少13.67%；其中营业收入为0.00美元，每股基本收益为-0.42美元。从资产负债表来看，Aura Biosciences, Inc.总负债30.67百万美元，其中短期债务3.13百万美元，资产负债比为0.07，流动比率为0.13。机构评级：截至2024年11月16日，当前有7家机构对Aura Biosciences, Inc.目标价做出预测，其中目标均价为22.43美元，其中最低目标价为20.00美元，最高目标价为24.00美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241116000322abc5160d&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241116000322abc5160d&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["AURA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2477352476","title":"Aura Biosciences, Inc.盘中异动 股价大跌5.15%报11.05美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2477352476","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2477352476?lang=zh_cn&edition=full","pubTime":"2024-10-22 23:47","pubTimestamp":1729612037,"startTime":"0","endTime":"0","summary":"北京时间2024年10月22日23时47分，Aura Biosciences, Inc.股票出现波动，股价急速下跌5.15%。Aura Biosciences, Inc.股票所在的生物技术行业中，整体跌幅为0.38%。Aura Biosciences, Inc.公司简介：Aura Biosciences Inc 是一家临床阶段的生物技术公司，正在开发精准免疫疗法，用于治疗一系列固体肿瘤，旨在保护受癌症影响的器官功能。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024102223471898e3dceb&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024102223471898e3dceb&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["AURA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.aurabiosciences.com","stockEarnings":[{"period":"1week","weight":0.0432},{"period":"1month","weight":-0.1253},{"period":"3month","weight":-0.1886},{"period":"6month","weight":-0.0398},{"period":"1year","weight":0.0162},{"period":"ytd","weight":0.1523}],"compareEarnings":[{"period":"1week","weight":-0.0067},{"period":"1month","weight":-0.0058},{"period":"3month","weight":0.024},{"period":"6month","weight":0.1628},{"period":"1year","weight":0.1448},{"period":"ytd","weight":0.1184}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Aura Biosciences, Inc.于2009年1月根据特拉华州法律注册成立。该公司是一家临床阶段的生物技术公司，开发治疗实体瘤的精确疗法，旨在保护器官功能。该公司的主要候选产品bel-sar正在进行后期临床开发，用于治疗早期脉络膜黑色素瘤患者，也正在进行其他眼部肿瘤适应症和膀胱癌症的临床开发。","yearOnYearQuotes":[{"month":1,"riseRate":0.4,"avgChangeRate":-0.016438},{"month":2,"riseRate":0.4,"avgChangeRate":0.024865},{"month":3,"riseRate":0.4,"avgChangeRate":-0.011666},{"month":4,"riseRate":0.2,"avgChangeRate":-0.052717},{"month":5,"riseRate":0.8,"avgChangeRate":0.068049},{"month":6,"riseRate":0.6,"avgChangeRate":-0.010121},{"month":7,"riseRate":0.6,"avgChangeRate":0.081681},{"month":8,"riseRate":0.2,"avgChangeRate":-0.095877},{"month":9,"riseRate":0.4,"avgChangeRate":0.040615},{"month":10,"riseRate":0.25,"avgChangeRate":-0.060725},{"month":11,"riseRate":0.6,"avgChangeRate":0.05644},{"month":12,"riseRate":0.2,"avgChangeRate":-0.095533}],"exchange":"NASDAQ","name":"Aura Biosciences, Inc.","nameEN":"Aura Biosciences, Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.50.1","shortVersion":"4.50.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Aura Biosciences, Inc.(AURA)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Aura Biosciences, Inc.(AURA)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Aura Biosciences, Inc.,AURA,Aura Biosciences, Inc.股票,Aura Biosciences, Inc.股票老虎,Aura Biosciences, Inc.股票老虎国际,Aura Biosciences, Inc.行情,Aura Biosciences, Inc.股票行情,Aura Biosciences, Inc.股价,Aura Biosciences, Inc.股市,Aura Biosciences, Inc.股票价格,Aura Biosciences, Inc.股票交易,Aura Biosciences, Inc.股票购买,Aura Biosciences, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Aura Biosciences, Inc.(AURA)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Aura Biosciences, Inc.(AURA)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}